Woojung Bio (XKRX:215380) Change In Payables And Accrued Expense : ₩0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Woojung Bio Change In Payables And Accrued Expense?

Woojung Bio's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was ₩0 Mil. It means Woojung Bio's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Woojung Bio's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ₩0 Mil. It means Woojung Bio's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Woojung Bio Change In Payables And Accrued Expense Historical Data

The historical data trend for Woojung Bio's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Woojung Bio Change In Payables And Accrued Expense Chart

Woojung Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Woojung Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Woojung Bio Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

Woojung Bio Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Woojung Bio's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Woojung Bio (XKRX:215380) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Woojung Bio Inc (XKRX:215380) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gwanggyo-ro 145, B-dong 3rd Floor, Next Generation Convergence Technology Research Center, Gyeonggi-do, Yeongtong-gu, Suwon-si, KOR

Website

http://bio.woojungbsc.co.kr

Woojung Bio Inc is engaged in the research and development of natural science and engineering. Its products include Gene Delivery, Antibody Production, Immunodeficiency model, Human-to-human model, Zika, Mers, Dengue, Influenza Virus Research, Influenza virus, vaccine studies, and Elegant Goettingen Mini Pig.

Woojung Bio (XKRX:215380) Headlines

No Headlines